Significance:
Cancer suppressor p53 is mutated in more than 50% of human cancers of different origin, while its pathway is altered in about 80% of tumors.
This study suggests a therapeutic strategy as to how p53-deficient/deleted or mutant p53 expressing human metastatic cancers can be cured by activating its unmutated or rarely mutated “homologous protein such as TAp63γ” .
Research Findings:
MiRNA-497, by decreasing the expression of its target genes, it may increase the expression of tumor suppressor TAp63γ. Thereby, it may inhibit the migration and invasion of metastatic cancer cells.
Therapeutic opportunity:
Given that MiR-497 may induce the expression of TAp63γ in p53-mutated human tumors, pharmacological formulations encompassing ” MiRNA-497 or its activators” may be used to inhibit the progression of p53-mutated invasive metastatic tumors. Taken together, this study suggests an MiRNA-based therapy for p53-mutated metastatic human tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-497 increases the expression of tumor suppressor p53 homologue TAp63γ and induces regression of p53-mutated human tumors via down regulation of its target gene, 5/October/2016, 8.14 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Amount: $300#
Results guaranteed if not refunded
Undisclosed information: How MiR-497 increases the expression of TAp63γ
#Research cooperation
Attention: Kindly understand that this idea was posted earlier by us, but then we lost it on our website because somebody had hacked our website in the second week of Oct, 2015. We are in the process of recovering our ideas posted earlier, especially from May, 2015 to October, 2015. So, this idea is re-posted for the sake of the researchers.